Inferra AIResearch Tools

Inferra AI / Company / ROIV

Roivant Sciences

ROIV · Health Care

Last earnings Aug 6, 2026

Important announcements

Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Oct 21, 2026

AI analysis

Q1 2025 · reported Aug 11, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

No extracted figures held

The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Judge s decision pending on the Markman hearing in the Pfizer/BioNTech case Roivant completed its $1.5 billion share repurchase program, including $208 million in repurchases for the quarter ending June 30, 2025, reducing outstanding shares by over 15% from March 31, 2024.

A new $500 million share repurchase program was approved by the board of directors in June 2025 Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.5 billion at June 30, 2025, supporting cash runway into profitability Roivant will host a live conference call and webcast at 8:00 a.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Roivant Sciences Q1 2025 results

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

Judge s decision pending on the Markman hearing in the Pfizer/BioNTech case Roivant completed its $1.5 billion share repurchase program, including $208 million in repurchases for the quarter ending June 30, 2025, reducing outstanding shares by over 15% from March 31, 2024.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

A new $500 million share repurchase program was approved by the board of directors in June 2025 Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.5 billion at June 30, 2025, supporting cash runway into profitability Roivant will host a live conference call and webcast at 8:00 a.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

ET on Monday, August 11, 2025, to report its financial results for the first quarter ended June 30, 2025, and provide a business update I am proud of our continued execution in this quarter, including clinical progress across our programs and the completion of our initial $1.5 billion share repurchase program, said Matt Gline, CEO of Roivant.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Our board has also approved an additional buyback program, reflecting our commitment to return capital to shareholders and to increase our exposure to our existing and future programs.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Roivant completed its $1.5 billion share repurchase program, including $208 million in repurchases this quarter, reducing outstanding shares by over 15% from March 31, 2024.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

A new $500 million share repurchase program was approved by the board of directors in June 2025.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Strategy & priorities

Our forward-looking statements include, but are not limited to, statements regarding our or our management team s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our product candidates following applicable regulatory approvals.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Our forward-looking statements include, but are not limited to, statements regarding our or our management team s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts.

SEC original ↗Roivant Sciences — 10-Q Quarterly report10-QAug 6, 2026

The Company s chief operating decision maker views the operations and manages the business in a single operating and reportable segment focused on the discovery, development and commercialization of medicines and technologies.

SEC original ↗Roivant Sciences — 10-Q Quarterly report10-QAug 6, 2026

Risks & headwinds

Genevant LNP litigation continues to progress with summary judgment phase ongoing in the U.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Actual results may differ materially from those contemplated in these statements due to a variety of risks, uncertainties and other factors.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.

SEC original ↗Roivant Sciences — Earnings release (8-K exhibit)EX-99Aug 11, 2025

Legal Proceedings 36 Item 1A.

SEC original ↗Roivant Sciences — 10-Q Quarterly report10-QAug 6, 2026

Legal Proceedings, Part II, Item 1A.

SEC original ↗Roivant Sciences — 10-Q Quarterly report10-QAug 6, 2026

Documents

Earnings deck slides

0 decks with slide view

Roivant Sciences — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Roivant Sciences — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Roivant Sciences — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Roivant Sciences — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Roivant Sciences — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Roivant Sciences — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

69 documents

Earnings releases

17 documents

Presentations

6 documents

Transcripts

0 documents

No transcripts for Roivant Sciences are held in this edition of the library.

Mentioned by

2 companies

Other tracked companies whose held documents mention Roivant Sciences by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.